Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Therefore, our results support the translational development of i.p. delivery of uPAR-targeted theranostic IONPs for image-guided treatment of peritoneal tumors.
|
28529645 |
2017 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
MV-m-uPA and MV-h-uPA are fully retargeted, species-specific, oncolytic measles viruses (MV) directed against murine or human urokinase receptor (PLAUR/uPAR), expressed in tumor and stromal cells.
|
28679779 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The aim of this study was to assess the feasibility of two uPAR-targeted probes for PET and fluorescence tumor imaging in a human xenograft tongue cancer model.
|
28039488 |
2017 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Elevated levels of PLAUR, a validated target gene, and CDH11 were confirmed in tumors with low expression of miR-335.
|
29075357 |
2017 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
FOXA2 deletion (FOXA2Δ) by using two CRISPR/Cas9 vectors in PANC-1 cells induced tumor growth in vivo resulting in upregulation of PLAUR and ERK pathways in FOXA2Δ xenograft tumors.
|
27151939 |
2016 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Targeted delivery of antisense-miR-21 and antisense-miR-10b coloaded urokinase plasminogen activator receptor (uPAR) targeted polymer NPs treated mice showed substantial reduction in tumor growth at very low dose of 0.15 mg/kg, compared to the control NPs treated mice and 40% reduction in tumor growth compared to scramble peptide conjugated NPs treated mice, thus demonstrating a potential new therapeutic option for TNBC.
|
25652012 |
2015 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Histological analysis showed that a high level of uPAR-targeted nanoparticles was present in the tumor edge or active tumor stroma immediately adjacent to the tumor cells.
|
24396518 |
2013 |
Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Nicotine stimulates urokinase-type plasminogen activator receptor expression and cell invasiveness through mitogen-activated protein kinase and reactive oxygen species signaling in ECV304 endothelial cells.
|
22261521 |
2012 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Small-animal PET was performed in 3 human cancer xenograft mice models, expressing different levels of human uPAR, and the tumor uptake was correlated with the uPAR expression level determined by uPAR enzyme-linked immunosorbent assay.
|
22213823 |
2012 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We have reported here on the dual role of TLR3 in pharynx metastatic cell line (Detroit 562); on one hand TLR3 activation drove cells to apoptosis while on the other its stimulation contributed to tumor progression by altering the expression of tumor promoting genes (PLAUR, RORB) and enhancing the cell migration potential.
|
21735101 |
2011 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We used the suppression subtractive hybridization technique to subtract cDNAs prepared from tumor and normal human esophageal samples. cDNA sequencing and reverse transcription polymerase chain reaction (RT-PCR) analysis of RNAs from human tumor and the normal esophagus revealed 10 differentially transcribed genes: CSTA, CRNN, CEACAM1, MAL, EMP1, ECRG2, and SPRR downregulated, and PLAUR, SFRP4, and secreted protein that is acidic and rich in cysteine upregulated in tumor tissue as compared with surrounding normal tissue.
|
19732125 |
2010 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We determined the distribution of genotypes and frequencies of alleles of the (CA)(n) repeat polymorphism in intron 3 of the urokinase plasminogen activator receptor (uPAR) gene, uPAR antigen levels and microvessel density (MVD) in tumour and distant mucosa samples from 52 patients with colorectal cancer.
|
18511987 |
2008 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors.
|
17297470 |
2007 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The review summarizes the most important transcriptional mechanisms regulating u-PAR gene, and will focus on the differential binding of transcription factors to u-PAR promoter elements from studies in resected tumour and normal tissues of colorectal and gastric cancer patients.
|
16617013 |
2006 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In 103 patients with colorectal cancer, electrophoretic mobility shift assay/supershift analysis for u-PAR promoter region -190/-171 was done in tumors and normal tissues.
|
16361535 |
2005 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In parallel, expression of Fos family members as determined by Western Blot analysis in 75 mammary carcinomas was correlated with MMP1, MMP9, PAI-1 and uPAR protein levels in the tumors.
|
15319566 |
2004 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
This study gives the first clinical evidence that urokinase-type plasminogen activator receptor (u-PAR) gene expression is tumor-specifically regulated via an activator protein (AP)-2/Sp1 promoter element in a large patient subpopulation.
|
12796395 |
2003 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.
|
11517932 |
2001 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The serine protease urokinase-type plasminogen activator (uPA) mediates cancer invasion and metastasis by binding to a cell surface receptor (uPA-R, CD87) on both tumor and stromal cells.
|
9681686 |
1998 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Annexin II is also overexpressed in some tumors (5/13). u-PAR is overexpressed in most tumor samples examined (14/15), while u-PA is weakly detected in a low number of cases (3/14); both u-PAR and u-PA are overexpressed in areas of tumor associated pancreatitis.
|
9482108 |
1998 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our study investigated uPAR gene variation in 92 CRC patients and in tumour DNA from a subset of 69 patients using the PLAUR-IVS3 marker located in an intron of this gene.
|
9667756 |
1998 |